Antisense compound and method for selectively killing activated t cells
CA 2539972 C · Owner: Avi Biopharma, Inc. · Inventors: Moulton, Hong Mu; Iversen, Patrick L.; Hinrichs, David J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein and a reverse TAT (rTAT) , polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigenactivated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 23, 2004 and granted May 16, 2017. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 23, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 23, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.